Korkolopoulou Penelope, Goudopoulou Athina, Voutsinas Gerassimos, Thomas-Tsagli Euphemia, Kapralos Panagiotis, Patsouris Efstratios, Saetta Angelica A
Department of Pathology, National and Kapodistrian University of Athens Medical School, Athens, Greece.
Urology. 2004 Jun;63(6):1198-204. doi: 10.1016/j.urology.2004.01.007.
To investigate the incidence of Fas (exon 9) mutations and the expression of Fas, Fas-Fas ligand (FasL) system, and cellular FLICE-like inhibitory protein (c-FLIP) in relation to standard clinicopathologic parameters and patient outcome in bladder carcinoma. Disruption of apoptotic cell death has been implicated in tumor aggressiveness in bladder urothelial carcinomas. The FasL system is involved in the execution of apoptosis induced by the immune system. c-FLIP protein constitutes an important endogenous inhibitor of Fas and other death receptor-mediated apoptosis.
The expression of Fas, FasL, and c-FLIP was quantified immunohistochemically in paraffin-embedded tissues from 53 patients for whom clinical information was available. DNA extracted from the same samples was screened for mutations in Fas exon 9 by single-strand conformation polymorphism and sequencing. The effect of Fas, FasL, and c-FLIP on clinical outcome was assessed by univariate and multivariate analyses.
Positive immunostaining was detected for Fas, FasL, and c-FLIP in 72%, 66%, and 81% of cases, respectively. Concurrent expression of Fas and FasL was seen in 27 samples (51%), of which 22 (81.5%) also displayed c-FLIP positivity. FasL and c-FLIP expression increased with advancing stage but was absent from normal urothelium. None of the 53 urothelial carcinoma samples analyzed showed evidence of mutations by polymerase chain reaction single-strand conformation polymorphism and direct sequencing. Survival analysis demonstrated that although both FasL and c-FLIP expression adversely affected survival, only c-FLIP remained statistically significant on multivariate analysis.
The frequent expression and coexpression of Fas, FasL, and c-FLIP in urothelial carcinomas implicates c-FLIP as an inhibitor of the Fas-FasL-induced death pathway in these tumors. Moreover, c-FLIP conveys independent prognostic information in the presence of classical prognosticators.
研究Fas(外显子9)突变的发生率以及Fas、Fas - Fas配体(FasL)系统和细胞FLICE样抑制蛋白(c - FLIP)的表达与膀胱癌标准临床病理参数及患者预后的关系。凋亡细胞死亡的破坏与膀胱尿路上皮癌的肿瘤侵袭性有关。FasL系统参与免疫系统诱导的凋亡过程。c - FLIP蛋白是Fas和其他死亡受体介导的凋亡的重要内源性抑制剂。
对53例有临床资料的患者石蜡包埋组织进行免疫组织化学定量检测Fas、FasL和c - FLIP的表达。从相同样本中提取的DNA通过单链构象多态性和测序筛选Fas外显子9中的突变。通过单因素和多因素分析评估Fas、FasL和c - FLIP对临床结局的影响。
分别在72%、66%和81%的病例中检测到Fas、FasL和c - FLIP的阳性免疫染色。27个样本(51%)中同时检测到Fas和FasL的表达,其中22个(81.5%)也显示c - FLIP阳性。FasL和c - FLIP的表达随分期进展而增加,但在正常尿路上皮中未检测到。通过聚合酶链反应单链构象多态性和直接测序分析,53例尿路上皮癌样本均未显示突变证据。生存分析表明,虽然FasL和c - FLIP的表达均对生存有不利影响,但多因素分析显示只有c - FLIP具有统计学意义。
Fas、FasL和c - FLIP在尿路上皮癌中的频繁表达和共表达表明c - FLIP是这些肿瘤中Fas - FasL诱导的死亡途径的抑制剂。此外,在存在经典预后因素的情况下,c - FLIP传达独立的预后信息。